Epitalon Side Effects: Incidence Rates Across Clinical Trials

What each human study reported

FDA identified two sublingual studies in night-shift workers and one study that injected epitalon beside the eye in retinitis pigmentosa [1].

In the sublingual study described in most detail, 75 healthy women aged 40 to 50 were enrolled, most of them night-shift workers; the 40 with low melatonin output were split into two groups of 20 and given a sublingual spray delivering about 0.5 mg per day, or placebo, for 20 days [1]. Urinary 6-sulfatoxymelatonin rose about 1.7-fold with epitalon and did not change with placebo. Researchers described improvement in mood and physical condition in 83% of the epitalon group versus 25% of the placebo group [1]. Sleep outcomes were not measured and blinding was not specified [1].

The retinitis pigmentosa study (Khavinson 2002) reports a 'positive clinical effect in 90% of the cases' in patients with degenerative retinal lesions [2]. Epitalon was injected beside the eye in that study [1]. A 2026 narrative review that searched through September 22, 2026 describes human evidence as limited to small physiological or biomarker studies and that older controlled study, with long-term safety data inadequate [3].

What FDA's adverse-event searches show

FDA searched its adverse-event database through December 8, 2025 and its food and supplement complaint system through December 5, 2025 and retrieved no epitalon reports [1]. FDA's dashboard notes that reports cannot be used to estimate incidence and are not by themselves an indicator of a product's safety profile [4].

The specific risk FDA cited for an injectable epitalon product is immunogenicity: injectable peptides may pose a risk from aggregation and peptide-related impurities [1][5]. FDA's compounding page states it has not identified safety-related information regarding epitalon for the proposed route of administration [5].

The cancer question FDA raised

In cultured human fetal fibroblasts that lack telomerase, epitalon induced telomerase activity and telomere elongation [6]. FDA warned that because it activates telomerase and lengthens telomeres, and longer telomeres are generally linked to higher cancer risk, epitalon has a mechanistic potential to be carcinogenic, and it found the mouse studies of cancer and chromosome damage too limited — one fixed dose, female mice only, short exposure — to show safety [1]. In a separate mouse study, HER-2/neu transgenic mice given 1 microgram of epitalon per mouse for 5 consecutive days each month developed fewer and smaller mammary tumors than saline-treated mice [7].

FDA found no pharmacokinetic data for epitalon, so there is no human half-life to report [1].

Where the 'no side effects' claim comes from

The phrase traces to a Russian-language abstract that said only 'no side effects', without a dose, route or number of people [1]. Epitalon is not FDA-approved, and FDA found no approved product in Canada, Australia, the UK, Belgium, Ireland, France, Norway, Germany, Spain or Italy, or authorized by the European Medicines Agency [1]. FDA staff proposed not adding epitalon to the bulks list [1]. The July 24, 2026 advisory committee vote in favor of adding it was advice only and not binding [8][9], and HHS's October 2026 draft enforcement-discretion policy states that it does not establish rights for any person and is not binding [9].